Adamas Pharmaceuticals has entered into a co-operative R&D agreement (CRADA) with the US Naval Health Research Center to test Adamas’ triple combination antiviral drug (TCAD) flu therapy.
Under the CRADA, the US Naval Health Research Center will conduct comparative tests of Adamas’ TCAD therapy against various strains of the influenza A virus, including seasonal influenza (H1N1, H3N2), avian influenza (H5N1) and novel influenza A/H1N1.
The study will allow the pharmaceutical company to assess the in-vitro activity of TCAD therapy against various pathogenic strains of the influenza A virus, as well as to compare the in-vitro activity of TCAD therapy to other pharmaceutical agents when used alone or in double combination.
Adamas chairman and CEO Gregory Went said that the collaboration with the US Naval Health Research Center, with its seminal work in discovering the novel influenza A/H1N1 virus, would significantly advance Adamas’ efforts to develop TCAD therapy.
“We look forward to partnering with the Naval Health Research Center to generate data to support the potential use of TCAD therapy for the military, healthcare workers and general public when faced with the global threat of influenza A outbreaks,” Went said.
Adamas is developing TCAD therapy as a potential broad-spectrum antiviral therapy for serious infections caused by influenza A viruses.